ClinicalTrials.gg
RecruitingNCT06893016Updated Jul 17, 2025

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

A Phase 3 interventional study of RAY1225 and Placebo in Obesity, sponsored by Guangdong Raynovent Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
61st of 502
640 · median 120
Started
2025
with 113 others
Phase 3
100 of 600
50 open now
Primary completion
2026-06
later than 68 of 280 live
Registered
333rd of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 61st largest by planned enrollment of the 502 interventional ones that give a count, is one of 114 that started in 2025, is one of 100 in phase 3, reaches primary completion later than 68 of the 280 other live ones, and was the 333rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. ≥ 28 kg/m2 or ≥24kg/m² to \<28 kg/m2 with at least 1 of the following weight-related comorbidities: a) Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or the use of at least one antihypertensive medication to maintain normal blood pressure;b) Fasting triglycerides (TG) ≥1.70 mmol/L, fasting low-density lipoprotein cholesterol (LDL-C) ≥4.1 mmol/L, fasting high-density lipoprotein cholesterol (HDL-C) \<1.04 mmol/L, or the need for at least one lipid-lowering treatment to maintain normal lipid levels; c) Obstructive sleep apnea syndrome; d) Fatty liver; e) Cardiovascular disease; e) Polycystic ovary syndrome.
  3. History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.

Exclusion criteria

Exclusion Criteria:

  1. Obesity known to be caused by monogenic mutations, other diseases, or medications.
  2. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.
  3. A history of moderate to severe depression at any time in the past or a score of ≥15 on the PHQ-9 questionnaire at screening; a history of bipolar disorder, schizophrenia, or other severe psychiatric disorders.
  4. A history of organ transplantation (excluding corneal transplant), or being currently prepared to undergo organ transplantation.
  5. Plans to quit smoking during the study period
  6. Allergic constitution (allergic to multiple medications or foods), or those known to be allergic to RAY1225, GLP-1 receptor agonists, or GLP-1 related drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
640 participants (estimated)

Study arms

  • Experimental
    RAY1225 High Dose

    Participants will receive RAY1225 high dose subcutaneously (SC) for 52 weeks.

    Drug: RAY1225

  • Experimental
    RAY1225 Medium Dose

    Participants will receive RAY1225 Medium dose subcutaneously (SC) for 52 weeks.

    Drug: RAY1225

  • Experimental
    RAY1225 Low Dose

    Participants will receive RAY1225 low dose subcutaneously (SC) for 52 weeks.

    Drug: RAY1225

  • Placebo comparator
    Placebo

    Participants will receive placebo SC for 52 weeks.

    Drug: Placebo

Interventions

  • RAY1225 will be administered SC

  • DrugPlacebo

    Placebo will be administered SC.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 52

    Time frame: Baseline and Week 52

  2. Number of Participants who Achieved a ≥ 5% Reduction in Body Weight from Baseline at Week 52

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Change From Baseline in Waist Circumference at Week 52

    Time frame: Baseline and Week 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 12 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 25, 2025
StartActual
Jun 15, 2025
Primary completionEst.
Jun 15, 2026
CompletionEst.
Sep 15, 2026
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06893016
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Jun 15, 2025
Primary completion
Jun 15, 2026 (estimated)
Completion
Sep 15, 2026 (estimated)
Last update
Jul 17, 2025

Study contacts

Ji, Doctor
Contact
pkuphiao@163.com
86-10-8831-6815

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilpatide

Start the discussion